Biotech Startups

Axio Biosolutions develops patented chitosan-based medical dressings for rapid bleeding control and wound care, aimed at managing severe bleeding and acute or chronic wounds. Its products target healthcare and emergency medical use with internationally certified technologies.

1 investor

Axiota develops an animal health platform focused on cattle products designed to help cattle thrive during transition and stress periods, serving cattle producers and consumers.

1 investor

Axoiya Bio develops phosphotyrosine enrichment reagents using proprietary superbinder technology to detect rare, low-abundance phosphorylation events for deeper phosphoproteome coverage. Its products serve researchers conducting phosphoproteomics studies in the life sciences.

1 investor

1 investor

Axsome Therapeutics is a biopharmaceutical company. The available page content is only an external-link disclaimer and does not describe the company's products or activities in detail.

1 investor

Axxam develops AXXSense, a cell-based platform for assessing taste and olfactory properties of pharmaceutical compounds during drug development. The platform uses human bitter taste receptors and trigeminal assays to predict bitterness and off-tastes early in the pipeline, helping pharmaceutical companies optimize formulations and reduce late-stage reformulation risks.

1 investor

Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)

1 investor

Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.

1 investor

Azane Therapeutics is a therapeutics company focused on nucleic acid delivery.

1 investor

Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.

1 investor

AZD CRO is a contract research organization providing end-to-end services for clinical trials and product registration, from early-phase studies (proof of concept, First in Human, Phase I) through Phase IV. It supports pharmaceutical and medical product developers with regulatory expertise across major agencies (FDA, EMA, ANVISA, and others), operating in Brazil with partnerships across the Americas, Israel, and Eastern Europe.

1 investor

Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology. The company leverages a proprietary platform combining a microbial library of approximately 1,500 bacterial strains with AI/ML-powered screening and genetic engineering technology.

1 investor

Aziyo Biologics (operating as Elutia) develops drug-eluting biomatrix products that combine biologic scaffolds with localized antibiotic delivery to reduce surgical complications in reconstructive and soft tissue repair procedures. The company commercializes biologic matrix products like SimpliDerm for soft tissue reconstruction and cardiovascular repair products, while advancing its next-generation NXT-41 and NXT-41x platforms for broader surgical applications.

1 investor

Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases. The company focuses on novel PARP inhibitors, PARG inhibitors, and OGG1 inhibitors as next-generation precision therapeutics.

1 investor

Azul Bio is a public benefit company that develops live biotherapeutics—custom microbial-based treatments—to help coral reefs resist heat-induced bleaching, disease, and pollution. It also provides coral treatment application, rapid biotherapeutic development, and marine genomics and microbiome analysis services for reef monitoring, coral aquaculture, and marine research.

1 investor

Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions. The company applies drug development expertise to address the core pathophysiology of these eye conditions.

1 investor

Azurecell is an early-stage company focused on restoring neural function, with no further product or service details disclosed on the page.

1 investor

Strategic Investment Group provides outsourced investment management for institutions, including strategic asset allocation policy design and back-office support. It offers customized investment solutions tailored to each institution's objectives, mission, and risk tolerance.

1 investor

BabyBiom is a Polish brand developing probiotic cosmetics for infants, newborns, and children that support the skin's natural microbiome from the first days of life, with particular focus on babies born via cesarean section. The company combines microbiology, biotechnology, and cosmetology, working on R&D projects to create skincare products.

1 investor

BacAlt uses fermentation to convert agricultural waste into fully natural bacterial biopolymers that replace synthetic ingredients. It supplies these functional biopolymers to formulators across sectors including home care, cosmetics, oral care, agri-chem, nutraceuticals, and pharmaceuticals.

1 investor

Bacterioscan develops diagnostic technologies and solutions for bacterial detection and identification. The company serves healthcare, pharmaceutical, and diagnostics markets.

1 investor

Baltic Sandbox Ventures is an early-stage investor and program operator running a 7-week equity-free incubation, a 6-month acceleration (Business Development Lab), and seed investments for deep-tech founders. It backs R&D-driven teams with scientific backgrounds building in domains such as AI/ML, life sciences (BioTech, MedTech), and hardware (robotics, IoT, space).

1 investor

Developed the first FDA-approved blood test to detect mild traumatic brain injuries.

1 investor

Banyu supplies Eucheuma Spinosum, a carrageenan-rich seaweed harvested in Indonesia and sold as raw material for food, cosmetics, and pharmaceutical processing. It targets companies seeking natural ingredients for global demand.

1 investor